David W. Pritchard
Director
Mr.Pritchard is President & Chief Executive Officer and joined KaloBios in 2006 with more than 25 years of experience in general management, business development and financial management within the biopharmaceutical industry. Prior to joining KaloBios, he held the position of CBO at Rinat Neuroscience Corporation, where he managed the negotiations on the acquisition of Rinat by Pfizer in 2006 for a reported $500 million. Prior to that, he was CFO at Matrix Pharmaceuticals and managed the sale of the company to Chiron Corporation in 2002 (now Novartis). Between 1992 and 2000 David served as VP, Business Development and CFO of Metabolex, Inc. where he completed three rounds of financing and negotiated four worldwide corporate alliances with major pharmaceutical companies. He started his biotechnology career at Triton Biosciences, Inc. as one of the founding managers, where he held various positions including heading up the sales and marketing efforts, commercial development, the cancer diagnostics business, and ultimately managed the sale of Triton (predominately to Schering AG, now Bayer). Triton developed Betaseron® for multiple sclerosis (2010 sales exceeded $1.5 billion), and Fludara® for leukemia. David holds an MBA degree from Stanford University and a BS in Chemical Engineering from Cornell.